

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16549 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number: **PCT/IL01/00790**
- (22) International Filing Date: 23 August 2001 (23.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/227,853 25 August 2000 (25.08.2000) US
- (71) Applicant (for all designated States except US): **YEDA RESEARCH AND DEVELOPMENT CO. LTD.** [IL/IL]; P.O. Box 95, Rehovot 76100 (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **COHEN, Irun, R.** [US/IL]; 11 Hankin Street, Rehovot 76354 (IL). **QUINTANA, Francisco, J.** [AR/AR]; Teniente B Matienzo, 1831 1H Capital Federal, 1426 (AR).
- (74) Agent: **WEBB, Cynthia**; Webb, Ben-Ami & Associates, P.O. Box 2189, Rehovot 76121 (IL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/16549 A2

(54) Title: METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE

(57) Abstract: The present invention relates to DNA vaccines useful for the prevention and treatment of ongoing autoimmune diseases. The compositions and methods of the invention feature the CpG oligonucleotide, preferably in a motif flanked by two 5' purines and two 3' pyrimidines. The vaccine may further comprise DNA encoding a specific antigen, or the peptide antigen itself. The invention is exemplified for IDDM.

METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE

FIELD OF THE INVENTION

5 The present invention relates to methods for the prevention or treatment of autoimmune diseases and particularly insulin-dependent diabetes mellitus (IDDM), and more particularly to such methods in which the vaccine includes a DNA molecule which includes a CpG motif.

BACKGROUND OF THE INVENTION

10 DNA vaccination is an efficient approach to induce protection against infectious pathogens (Tascon et al, 1996) and cancer (Stevenson et al, 1999), and to modulate autoimmune processes (Waisman et al, 1996). It has been shown that after intramuscular injection of a naked expression vector, plasmid DNA is taken up by muscle cells and
15 maintained episomally, allowing the expression of the encoded antigen (Wolff et al, 1992). Thus after single or repeated injections of DNA, cellular and/or humoral immune responses to the encoded protein are mounted, and long-lived memory lymphocytes are induced (Hassett et al, 2000). These memory cells may have regulatory functions and, therefore, might serve as tools for the modulation of autoimmune conditions.

20 The CpG oligodeoxynucleotide (CpG-ODN) is an immunostimulatory sequence present primarily in bacteria (Lipford et al 1998; Krieg et al 1998; and Krieg et al, 1999). Bacterial DNA contains immunostimulatory motifs consisting of a centralized unmethylated CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines (Klinman et al, 1997). CpG motifs are underrepresented in mammalian genomes, due to a
25 combination of CpG suppression and CpG methylation (Klinman et al, 1996). It has been reported that this motif stimulates Th1 responses *in vivo* (Klinman et al 1996). For this reason, it has been suggested that single stranded DNA containing this motif would serve as a powerful adjuvant for both humoral and cellular immune responses (Lipford et al 1997, Krieg et al 1998). It has also been reported that intratumoral injections of
30 phosphorothioate oligodeoxynucleotides with CpG motifs induce rejection of established tumors and thus represent a new immunotherapeutic approach in human gliomas, which

overcomes the need for the selection and purification of a tumoral antigen (Carpentier et al 2000).

International PCT application no. WO 99/52547 discloses vaccine compositions comprising CD-1 antigens or lipid antigen and a T-cell stimulating compound. One of the
5 claimed immune adjuvants is a CpG motif-containing adjuvant but it is not suggested that this motif is efficient without a specific antigen. The vaccine compositions are useful for disorders including autoimmune diseases.

International PCT application no. WO 00/014217 discloses G-motif oligonucleotide having effects on the immune system and use in gene therapy. The invention relates also to
10 the use of the claimed oligonucleotides for the production of a pharmaceutical compositions for preventing or treating disorders including autoimmune diseases and Th1-mediated diseases.

International PCT application no. WO 99/58118 discloses methods for regulating hematopoiesis using CpG-oligonucleotides. The invention relates to methods for regulating
15 hematopoiesis using CpG-containing oligonucleotides for treatment of immune system disorders. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to method of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.

20 US patent no. 5,856,462 discloses oligonucleotides having modified CpG dinucleotides useful for studies of gene expression and for the antisense therapeutic approach. The invention provides modified oligonucleotides that inhibit gene expression and that produce fewer side effects than conventional phosphorothioate oligonucleotides. The invention further provides methods for using such oligonucleotides to modulate gene
25 expression in vivo, including such use for therapeutic treatment of diseases caused by aberrant gene expression.

In addition to DNA vaccination, other antigen specific treatments of autoimmune diseases have been proposed. Peptide therapy has been suggested for several autoimmune diseases mediated by cellular immune responses, including IDDM. It is thought that
30 peptide therapy may be the way to modulate an ongoing immune process.

The NOD mouse spontaneously develops insulin dependent diabetes mellitus (IDDM) as a consequence of an autoimmune process that leads to destruction of the insulin-producing β cells of the pancreas (Tisch et al, 1996). Several antigens have been identified as targets for diabetogenic T cells, including β -cell specific proteins such as insulin, non- β -cell restricted antigens such as GAD, and even ubiquitous antigens such as heat shock protein 60 (Hsp60, Tisch et al, 1996). It has been shown that the onset of diabetes is preceded by an increase in T cell reactivity towards Hsp60 and to an Hsp60 peptide comprising amino acids 437 and 460 of the intact molecule, named p277 (Elias et al, 1991). In contrast to the early T-cell reactivity, antibodies to Hsp60 and p277 can only be detected late in the natural history of the disease, months after the onset of clinical diabetes, when the destructive process has terminated (Krause et al, 1999). Peptide p277 administered to NOD mice in incomplete Freund's adjuvant can arrest the development of diabetes (Elias et al, 1995). Furthermore, p277 treatment is able to induce remission of advanced insulinitis even after the clinical onset of hyperglycemia (Elias et al, 1994). Successful treatment is associated with down-regulation of spontaneous T-cell reactivity to p277 and with the induction of antibodies to p277; these antibodies have Th2 associated isotypes (IgG1 and IgG2b), otherwise not found in young NOD mice (Elias et al, 1997; Ablamunits et al, 1998).

The effect of bacterial DNA on autoimmune inflammation is known. Bacterial DNA contains immunostimulatory motifs consisting of a central unmethylated CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines (Klinman et al, 1997). CpG motifs are under-represented in mammalian genomes, due to a combination of CpG suppression and CpG methylation (Klinman et al, 1996). However, modulation of autoimmune conditions by bacterial DNA has been already reported. Gilkeson et al (1996), demonstrated that immunization with bacterial DNA can modulate renal disease in autoimmune NZB/NZW mice, while calf thymus DNA was not effective (Gilkeson, 1996). Furthermore, improvement in renal disease was associated with the induction of antibodies to glomerular antigens immediately after immunization (Gilkeson et al, 1996). Boccaccio and her colleagues have reported that non-coding plasmid DNA can inhibit EAE attributed to its ability for activating $\text{IFN}\gamma$ *in vivo* (Boccaccio et al, 1999).

Nowhere in the prior art it is taught or suggested that DNA molecules which includes a CpG motif may be used as a vaccine for prevention or treatment of an naturally ongoing or spontaneous autoimmune disease in general or IDDM in particular.

5

SUMMARY OF THE INVENTION

It is an object of the present application to provide vaccines comprising a DNA molecule which includes a CpG motif. It is another object of the invention to provide methods for the prevention or treatment of autoimmune diseases, particularly insulin-dependent diabetes mellitus (IDDM).

10

In order to explore the potential of a DNA-based therapy of diabetes, the present inventors set out to investigate whether immunization with a DNA construct encoding the heat shock protein-60 (Hsp60) could modulate autoimmunity and prevent the onset of the disease. Surprisingly, not only the Hsp60 containing construct, but also the empty vector (pcDNA3) were capable of reducing the incidence of diabetes. Indeed, the CpG oligonucleotide motif present in the construct could, by itself, be used to inhibit the development of NOD diabetes. Despite the absence of Hsp60, effective treatment was associated with specific immune effects on Hsp60 autoreactivity: down-regulation of the spontaneous T-cell proliferation to Hsp60 and to its peptide analog p277(Val⁶-Val¹¹) and the induction of specific antibodies to these molecules.

15

20

Accordingly, the present invention relates to a method for the treatment or prevention of autoimmune diseases by administering a DNA vaccine which is a molecule which includes a CpG motif. The CpG motif is preferably the dinucleotide CG flanked on the 5' side by two purines and on the 3' side by two pyrimidines and is most preferably AACGGT.

25

The present invention further relates to DNA vaccines comprising DNA sequences encoding a peptide or polypeptide antigen associated with autoimmune diseases, particularly IDDM.

30

These vaccines, may further include DNA encoding an antigen which has previously been used for the treatment of diabetes including Hsp60, p277, p277(Val⁶-Val¹¹) and p12 as well as any other such antigen disclosed, for example, in U.S. patents 5,780,034 , 6,096,314, 6,180,103 and 6,110,746 and in international publications

WO96/19236 and WO97/01959 (the entire contents of each of which being hereby incorporated herein by reference), rather than DNA encoding such antigens, the vaccine may also include the peptide or polypeptide antigens themselves. These peptide or polypeptide antigens may be administered simultaneously with or independent from the DNA vaccine. Methods for prevention and treatment autoimmune diseases comprising administering such DNA vaccines alone or together with such DNA or peptide molecules are within the scope of the present invention.

Use of a DNA molecule comprising a CpG motif for the preparation of a vaccine for treatment or prevention of an ongoing autoimmune disease, especially IDDM, represent another aspect of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are graphs showing antibodies to Hsp60 in BALB/c mice immunized with the plasmid pHsp60.

Figure 2 is a graph showing prevention of NOD diabetes by DNA vaccination.

Figure 3 is a graph showing reduction of insulinitis by DNA vaccination.

Figures 4A and 4B are graphs showing proliferative responses to Hsp60 and p277(Val⁶-Val¹¹) in DNA-vaccinated mice.

Figures 5A and 5B are graphs showing induction of antibodies to Hsp60 and p277(Val⁶-Val¹¹) by vaccination with plasmids or the CpG oligonucleotide.

Figure 6 is a graph showing prevention of NOD diabetes by CpG injection.

Figures 7A and 7B are graphs showing isotypes of antibodies to Hsp60 and p277(Val⁶-Val¹¹) induced by vaccination with plasmids or the CpG oligonucleotide.

Figures 8A and 8B are graphs showing production of IL-10 and IFN γ in response to the CpG oligonucleotide in NOD spleen cell cultures.

Figure 9 is a graph showing that activation of splenocytes with CpG leads to Hsp60 release.

DETAILED DESCRIPTION OF THE INVENTION

It is an object of the present application to provide vaccines comprising a DNA molecule which include a CpG motif. It is another object of the invention to provide methods for the prevention or treatment of autoimmune diseases, particularly insulin-dependent diabetes mellitus (IDDM).

The present invention was discovered in the course of an investigation to test the effectiveness of DNA vaccination with Hsp60 as a specific immunotherapy for NOD diabetes. The specific immunogenicity of the pHsp60 plasmid in BALB/c mice (Figures 1A and 1B) was first ascertained. However, three unexpected observations were made when DNA treatment was used in NOD mice.

First, the pcDNA3 plasmid, which did not contain any sequences encoding Hsp60, was as effective in inhibiting the development of diabetes as was the pHsp60 plasmid (Figures 2 and 3). Secondly, the pcDNA3 plasmid, despite the absence of Hsp60, could still induce specific effects on the autoimmunity to Hsp60 intrinsic to the NOD diabetogenic process: down-regulation of T-cell proliferation and the induction of IgG2b antibodies to whole Hsp60 and to its peptide analog p277(Val⁶-Val¹¹). Responses to other antigens implicated in NOD diabetes, GAD and insulin, were not detected (Figures 4A, 4B, 5A, 5B, 7A and 7B). Thirdly, the CpG oligonucleotide by itself could essentially reproduce the effects of the pcDNA3 plasmid on Hsp60 autoimmunity and on the diabetes (Figures 5A, 5B, 6, 7A and 7B).

The CpG oligonucleotide is an immunostimulatory sequence present primarily in bacteria (Lipford et al, 1998; Krieg et al, 1998; and Krieg, 1999), and the present results using CpG might explain one of the mechanisms by which bacterial infections can inhibit the development of diabetes in NOD mice (Atkinson et al, 1999); bacterial infections may supply CpG stimulation.

It is noteworthy that the antibodies to Hsp60 and to peptide p277(Val⁶-Val¹¹) were of the IgG2b isotype (Figures 7A and 7B). The cytokine required for the production of IgG2b antibodies is TGF α , known for its suppressive effects (McIntyre et al, 1993 and Snapper et al, 1993). TGF α is a Th2-associated cytokine, which has been shown to protect NOD mice from diabetes (King et al, 1998). Although DNA vaccination also induced Hsp60 and p277(Val⁶-Val¹¹) specific antibodies of the IgG2a subclass, considered to be IFN γ dependent, the amount of these antibodies was significantly less than the amount of IgG2b antibodies. Thus, the cytokine balance was weighted more towards a Th2 response, suggesting that the therapeutic effects of DNA might be related to the activation of Th2-like T cells. Activation of Th2-like T cells was also described when spontaneous diabetes of NOD was prevented by the administration of the Hsp60 derived peptides p12 or p277 (Elias et al, 1997 and Bockova et al, 1997). Such T cells might suppress the Th1 T cells thought to be involved in the damage to the β -cells (Bockova et al, 1997).

The origin of the antibodies to Hsp60 and p277(Val⁶-Val¹¹) in mice protected from diabetes by pcDNA3 or treatment with the CpG oligonucleotide, or induced by the CpG oligonucleotide (Figure 5A) is strain specific. BALB/c mice did not produce these antibodies when injected with pcDNA3 (Figure 1A). NOD mice seem to manifest a spontaneous autoimmune response to Hsp60 and p277(Val⁶-Val¹¹), which is depicted in Figures 4A and 4B. Immunity to Hsp60 and p277 manifests as a peak of T cell reactivity before the onset of the disease (Elias et al, 1999 and Birk et al, 1996). Months after the onset of overt diabetes, antibodies to Hsp60 and p277 can be detected (Krause et al, 1999). After DNA treatment, the T cell proliferative response was diminished and replaced by the production of antibodies, mostly IgG2b. This suggests that the pre-existing autoimmune response, spontaneously arising in NOD mice, changes its phenotype after activation by bacterial DNA or CpG motifs, leading to the induction of Th2-like, IgG2b antibodies. Similarly, prevention of NOD diabetes by idiotypic induction of lupus with a monoclonal antibody was also associated with the induction of specific antibodies to Hsp60 and p277 (Krause et al, 1999). Thus, even when the induction of antibodies to Hsp60 and to p277 does not result from specific immunization, the appearance of such antibodies seems to serve as an indicator of the arrest of the diabetogenic process.

The CpG motif stimulates Th1 responses *in vivo* (Klinman et al, 1996).

Unexpectedly, this motif classically associated with a Th1 phenotype is now disclosed to be effective in inhibition of diabetes, known to be Th2 mediated. This paradox has been observed in animal models of spontaneous diabetes. Poly-I:C, IFN γ , IL-12, TNF α and IL-18, all of them well known inducers or mediators of Th1 responses, were shown to decrease insulinitis and prevent diabetes (Campbell et al, 1991; Nicoletti et al, 1998; Rothe et al, 1999; Serreze et al, 1989; Sobel et al, 1998; and Yang et al, 1994). Furthermore, in the case of IL-18, protection was associated with systemic activation of Th1 type immunity, together with a shift to a Th2 phenotype of the cells infiltrating the islets (Rothe et al, 1999). Therefore, non-specific stimulation of the NOD immune system, even by Th1 inducers, is able to reset the ongoing immune response to islet antigens and arrest the diabetogenic process.

When the effect of the CpG oligonucleotide on NOD spleen cells was analyzed *in vitro*, it clearly induced IFN γ and IL-10, in a dose dependent manner (Figures 8A and 8B). However, when the amounts of cytokine produced by CpG were compared to those triggered by Con A stimulation, it was evident that the effect of the CpG motif favored on the release of IL-10. Perhaps the prominence of IL-10 is important in modulating the diabetogenic process.

It was further found that the effect of CpG on the natural course of spontaneous NOD-diabetes appears to involve two mechanisms: a. a non-specific effect on APC function. b. a specific effect on the T-cell response to diabetes associated antigens. As demonstrated herein, CpG stimulation of splenocytes leads to the upregulation and secretion of Hsp60, and the activation of Hsp60-specific T-cells. Furthermore, in comparison to activation of Hsp60-specific T-cells through the addition of exogenous peptide, CpG stimulation shifts the phenotype of activated T-cells towards Th2. Since Hsp60 T-cells directed to the p12 and p277(Val⁶-Val¹¹) epitopes have been shown to regulate the progression of spontaneous NOD-diabetes, the effect of CpG on activated anti-p277(Val⁶-Val¹¹) and anti-p12 Th2 immunity might explain its modulatory effect on diabetes.

In addition, CpG affects APC function in NOD mice, probably through an IL-10 mediated mechanism. This change in APC function leads to downregulation and shift of

the self-reactivity directed to diabetes-associated antigens from the pathogenic Th1 phenotype to a protective Th2 response.

Without being restricted to any particular mechanism, it is speculated that, prevention of NOD-spontaneous diabetes by CpG involves the specific regulation of Hsp60
5 T-cell mediated autoreactivity, as well as changes in APC function that led to spreading of the Th2 shift to other diabetes-associated antigens.

Accordingly, the present invention is directed to a method for the prevention of all autoimmune diseases and particularly for the prevention of insulin-dependent diabetes mellitus (IDDM). The method involves vaccinating individuals with an effective amount
10 of a DNA vaccine which includes a CpG motif. This same method of vaccination can be used for the treatment of autoimmune diseases and particularly for the treatment of IDDM.

The oligonucleotide with a CpG motif is preferably one which includes the dinucleotide CG flanked on the 5' side by two purines and on the 3' side by two pyrimidines. The nucleotides A and G are purines and the nucleotides C and T are
15 pyrimidines. The precise purines and pyrimidines can vary, although the motif is preferably AACGTT. This six nucleotide motif is the smallest size that can be used for the vaccine, but the total length of the construct used for the vaccine is unlimited as is evidenced by the efficacy of the pcDNA3 empty vector which contains this motif. Those of ordinary skill in the art will be aware of oligonucleotides containing the CpG motif which
20 have been used in the literature for various experimentation and any of these oligonucleotides can be used for the purpose of the present invention. The oligonucleotide of SEQ ID NO:2 is only one non-limiting example of such an oligonucleotide. It will be noted that SEQ ID NO:2 contains two units with a CpG motif. Constructs with greater multiples of the CpG motif may also be made and are considered part of the present
25 invention.

While the Pur-Pur-C-G-Pyr-Pyr motif is the most common motif for the CpG motif, those of ordinary skill in the art will understand that the CpG motif has been known to take other forms as well. One such previously disclosed motif is
Pur-Pur-C-G-Pyr-Pur-C-G-Pyr-Pyr. Some non-limiting examples of CpR-ODNs which
30 have been used in the literature and may also be used in the present invention include:
TCCATGACGTTCTGACGTT (Brazolot Millan et al, 1998),

TCTCCCAGCGTGCGCCAT (Weiner et al, 1997), GAGAACGCTCGACCTTCGAT (Weiner et al, 1997), TCTCCCAGCGTGCGCCAT (Wooldridge et al, Blood, 89:2994-2998 (1997), TCGTCGTTTTGTCGTTTTGTCGTT (Hartmann et al, PNAS 96:9305-9310 (1999), TCGTCGTTCCCCCCCCCCCC (Hartmann et al (1999).

5 Preferably, the oligonucleotides are synthesized with a phosphorothioate modified backbone to improve their nuclease resistance.

The art of DNA vaccination is well established and those of ordinary skill in the art are aware of amounts and techniques which are commonly used with respect to such vaccination. DNA vaccines may be administered by intramuscular injection of pure
10 plasmid (i.e., naked) DNA, although the DNA may also be given by intradermal injection or coated onto microscopic gold particles that are introduced biolistically with a gene-gun into cells of the epidermis, all as is well-known in the art. The CpG motifs are preferably unmethylated as its activity as a vaccine may be lost if the CpG motif is methylated. The gene-gun administration approach may be preferred as it has been reported to be associated
15 with a relatively stronger Th2 response to the antigen, whereas i.m. injection of DNA vaccines is associated with a Th1 response (Raz et al 1996). Also as is known, the technique of DNA vaccination may include a postimmunization at an appropriate time following the initial administration, such as, for example, 18 days following the initial injection, or a more substantial period thereafter, such as 12 weeks.

20 The amounts of DNA to be used in the vaccine are also well-known to those of ordinary skill in the art and can be readily optimized by empirical observation. The amount is preferably between about 1 µg to about 500 µg, although amounts outside of this range may also be used in appropriate circumstances.

The invention is exemplified by the following non-limitative examples:

25

EXAMPLES

Methods

Mice

Female mice of the NOD/LtJ strain were raised and maintained under pathogen-free
30 conditions in the Animal Breeding Center of The Weizmann Institute from breeders kindly supplied by Dr. E. Leiter of Jackson Laboratories. These mice manifest insulinitis beginning

at about one month of age, which progresses to overt hyperglycemia beginning at about three months of age. The cumulative incidence of IDDM rises to 85% or greater by six months of age. Female BALB/c mice were also raised in the Weizmann Institute.

Construction of DNA Vaccine

5 The DNA vaccine was constructed using the pcDNA3 vector (Invitrogen, NV, Leek, The Netherlands). This is a well-known general purpose cloning and expression vector containing the CMV immediate-early promoter, a polylinker and the bovine growth hormone polyadenylation site. This vector also expresses neomycin resistance in eukaryotic cells. Its restriction map and nucleotide sequence have been published. This sequence is
10 set forth herein as SEQ ID NO:1.

 The full length cDNA of human the *hsp60* gene was cloned into the pcDNA3 vector under the control of the human cytomegalovirus (CMV) promoter. In brief, *hsp60* cDNA in pGEM was amplified by using specific oligonucleotides containing restriction sites for the enzymes BamHI or HindIII. The amplicon and the pcDNA3 vector were
15 purified and digested with BamHI/HindIII. The digested PCR product coding for Hsp60 and the linearized pcDNA3 vector were ligated using T4 DNA ligase, according to the standard protocol given by the manufacturer. The ligated plasmid was transformed into *Escherichia coli*, and later, sequenced to confirm correct insertion of the cDNA (data not shown).

20

Plasmid Preparation and Injection

 Large-scale plasmid DNA preparations were produced by the alkaline lysis method using Qiagen Plasmid Mega Prep (Qiagen, Santa Clarina, CA, USA). DNA was ethanol precipitated and resuspended in sterile PBS. Spectrophotometric analysis revealed 260 /
25 280 nm ratios ≥ 1.80 . Purity of DNA preparations was confirmed on a 1% agarose gel. Endotoxin levels were checked by *Limulus* Amoebocyte Lysate and always found to be under acceptable levels for *in vivo* use (less than 0.02 EU / μ g DNA).

 Eight-week-old NOD or BALB/c females were injected with 100 μ l of 10 mM cardiotoxin (Sigma, Rehovot, Israel) into the tibialis anterior muscle using a sterile 27G
30 syringe, fitted with a plastic collar to limit needle penetration to 2 mm. Five, twelve and

nineteen days later, the mice were injected with 100 μ l, 1 μ g/ μ l, of the desired DNA vaccine, or with PBS as controls.

Phosphorothioate oligonucleotides were synthesized at the Oligonucleotide Synthesis Unit of the Weizmann Institute of Science. One hundred microliters (1 μ g/ μ l) of each preparation were injected as above, following the same time schedule. The oligonucleotide CpG contains two 9 mer segments, which are present in the pcDNA3 ampicillin resistance gene. The control oligonucleotide GpC displays the same nucleotides with an inverted motif.

Oligonucleotide CpG: 5'-TCCATAACGTTGCA-AACGTTCTG-3' (SEQ ID NO:2).

10 Oligonucleotide GpC: 5'-TCCATAAGCTTGCAAAGCTTCTG-3' (SEQ ID NO:3).

Blood Glucose

Hyperglycemia was defined as a blood glucose level exceeding 13 mM, tested using a Beckman Glucose Analyzer II (Beckman Instruments, Brea, CA, USA).

Peptides and Antigens

15 Peptides were synthesized by a standard Fmoc procedure, as described (Elias et al, 1994). The peptides were purified by reverse-phase HPLC and their compositions were confirmed by amino acid analysis. The Hsp60 peptide analog denoted p277(Val⁶-Val¹¹), used in this study has the following amino acid sequence:

VLGGGVALLRVIPALDSLTPANED (SEQ ID NO:4). This analog of Hsp60 was disclosed in U.S. patent No. 6,180,103. Another Hsp60 analog denoted herein p12 has the sequence: EEIAQVATISANGDKEIGNI (SEQ ID NO:5). This analog was disclosed in U.S. patent No. 6,110,746. Insulin and Glutamic Acid Decarboxylase (GAD) were purchased from Sigma (Sigma, Rehovot, Israel). Recombinant Hsp60 was prepared as described Elias et al, 1991). Concanavalin A was purchased from Sigma.

25 T Cell Proliferation

Groups of 8-week-old female NOD mice received three weekly injections of PBS, pcDNA3 or pHsp60, as described. Four weeks after the last dose, the spleens were removed and the T-cell proliferative responses were assayed *in vitro* in response to the T-cell mitogen Con A, the p277(Val⁶-Val¹¹) peptide or the Hsp60 protein (Elias et al,

1999). Dose-response curves were done to establish optimal doses (not shown). The concentration of 10 µg/ml was chosen for the Hsp60 protein, 1 µg/ml was chosen for p277(Val⁶-Val¹¹), and 1.25 µg/ml for Con A to illustrate the results because these concentrations produced the optimum response. T-cell responses were detected by the incorporation of [methyl-³H]thymidine added to the wells in quadruplicate cultures for the last 18 hours of a 72 hour culture. The stimulation index (SI) was computed as the ratio of the mean c.p.m. of antigen- or mitogen-containing wells to control wells cultured without either. The SD from the mean c.p.m. were always < 10%. Background c.p.m. in the absence of antigens, was 800-1500 c.p.m.

10 Cytokine Assays

Spleen cells were prepared from 10-week-old NOD females. The spleen cells were incubated in triplicate with medium alone, or with increasing concentrations of the CpG or the GpC oligonucleotides. Supernatants were collected at 48 hrs. Cytokines in supernatants were detected by ELISA using Pharmingen paired antibodies (Pharmingen, San Diego, CA), according to the Pharmingen cytokine ELISA protocol. Pharmingen recombinant mouse cytokines were used as standards for calibration curves. The concentrations of cytokines are shown as the mean ng/ml derived from calibration curves using recombinant cytokines as standards.

ELISA Assay

20 Mouse sera were tested for antibodies binding to the p277(Val⁶-Val¹¹) peptide or to Hsp60 as described (Elias et al, 1997). Briefly, 10 µg/ml of the various antigens were applied to assay microplates (Maxisorp:Nunc, Roskilde, Denmark), and the plates were incubated with the test sera. The binding of antibodies was detected using alkaline phosphatase-conjugated anti mouse IgG, or isotype-specific anti-mouse IgG1, IgG2a or 25 IgG2b (Jackson ImmunoResearch). A significant amount of antibody was defined as an OD 405 nm reading higher than 0.25, which is 3 SD above the mean ELISA reading obtained using the sera of ten normal BALB/c mice.

Pancreas Histology

Mice from each treatment group were killed at the age of six months, when almost all the non-treated mice or control-treated NOD mice were sick. The pancreata were fixed in 10% buffered formalin, cut and stained by standard hematoxylin and eosin (H&E), and the average degree of insulitis was assessed over 20 islets scored per pancreas. The islets where classified as clear, when no infiltrate was detected; mildly infiltrated, when peri-insulitis or an intra-islet infiltrate occupying less than 25% of the islet were detected; infiltrated, when 25-50% of the islet was occupied by intra-islet inflammatory cells; and heavily infiltrated, when more that 50% of the islet was occupied.

Statistical Significance

The InStat 2.01 program was used for statistical analysis. Student's *t*-test and the χ^2 -test were carried out to assay significant differences between experimental and control groups.

Results

Hsp60 DNA Specifically Immunizes BALB/c Mice.

To test whether the pcDNA3 containing human Hsp60, here named pHsp60, was specifically immunogenic, female BALB/c mice were injected twice (days 5 and 23) i.m., with 100 μ g of pcDNA3 or pHsp60, and assayed periodically for serum antibodies.

Figure 1A shows that the BALB/c mice immunized with pHsp60 developed specific anti-Hsp60 IgG antibodies, whereas no antibodies to the Hsp60 protein could be detected in those animals immunized with pcDNA3. Groups of five 8-week-old female BALB/c were pretreated with cardiotoxin (day 0) and immunized i.m. on days 5 and 23 with pHsp60, pcDNA3, or PBS, or were left untreated. The arrows indicate the time of injections. Serum samples were taken before treatment with cardiotoxin, and ten days after each injection, and antibodies to Hsp60 (Fig. 1A), and to GST (Fig. 1B) were measured by ELISA. The antibodies to GST are shown ten days after the last injection. The means \pm SD are shown (a single asterisk denotes $P < 0.02$ compared to pcDNA3 treated mice, double asterisk denotes $P < 0.005$ compared to pcDNA3 treated mice, a plus sign denotes $P < 0.05$ compared to pHsp60 treated mice after the first dose of DNA).

Anti-Hsp60 specific antibodies were detected as early as 14 days after a single DNA injection ($p < 0.02$ in comparison to pcDNA3 vaccinated controls). A booster effect was evident ten days after the second DNA injection ($p < 0.05$ in comparison to the same group after the first dose, $p < 0.005$ compared to pcDNA-vaccinated mice). The immune response induced by DNA vaccination with pHsp60 was specific; pHsp60 did not induce antibodies to the non-related recombinant protein Glutathion S-Transferase (GST), as shown in Figure 1B. These results demonstrate that the pHsp60 construct, but not the empty pcDNA3 vector, can induce in BALB/c mice significant amounts of specific antibodies after one vaccination, and increasing titers after boosting.

10

DNA Injection Inhibits the Development of NOD Diabetes

To test whether immunization with pHsp60 might modulate the development of spontaneous diabetes in NOD mice, the present inventors vaccinated groups of eight-week old female NOD mice, three times at weekly intervals, and followed their glucose levels. Figure 2 shows the cumulative incidence of diabetes. Female NOD mice were allocated to groups of 17–18 mice each, and were immunized with PBS, pcDNA3 or pHsp60. A control group was left untreated. The pcDNA3 and Hsp60 vaccinated groups developed a significantly lower incidence of diabetes (a single asteriks denotes $P < 0.001$ compared to PBS treated mice, double asterisk denotes $P < 0.002$ compared to PBS treated mice).

It can be seen that both untreated animals and those treated with PBS developed the expected incidence of diabetes for NOD females; around 90% of them were sick by the age of six months. Those vaccinated with pHsp60, and surprisingly, also those vaccinated with the empty pcDNA3 construct showed a significant reduction in the incidence of diabetes. Only about 41% of those treated with pHsp60 ($p < 0.002$) and 38% of those treated with pcDNA3 ($p < 0.001$) were diabetic at the age of six months. Thus DNA vaccination modulates the onset of diabetes by a mechanism that is not associated with the presence of the *hsp60* gene in the administered vector.

At the end of the observation period, when the mice were six months old, the pancreata were obtained for histological examination. Figure 3 shows that 40-50% of the islets obtained from the non-treated or PBS treated mice were heavily infiltrated, and only 5-10% of the islets were free from insulinitis. In contrast, 50-70% of the islets obtained from

DNA-treated mice were free from insulinitis: $p < 0.001$ both for the pcDNA3 injected mice and for the pHsp60 group, compared to non-treated mice or to those treated with PBS. The differences between the groups treated with pHsp60 and pcDNA3 were not significant.

Eight-week-old NOD females were injected with PBS, pcDNA3 or pHsp60 as described in the legend to Figure 2, or left untreated and their pancreata were removed at the age of six months. The degree of insulinitis was determined by scoring at least 20 islets in each pancreas. The islets are depicted as clear (open bars), peri-insulinitis or an intra-islet infiltrate occupying less than 25% of the islet (light gray bars), an intra-islet infiltrate occupying 25–50% of the islet (dark gray bars), and an intra-islet infiltrate occupying more than 50% of the islet (black bars). The single asterisk denotes $P < 0.001$ compared to PBS treated mice.

Therefore, DNA vaccination, either with a vector encoding human Hsp60 (pHsp60) or with an empty vector (pcDNA3), diminished the incidence of spontaneous diabetes in NOD females. This effect was accompanied by a significant increase in the number of pancreatic islets remaining free of insulinitis.

Inhibition of T cell Proliferation to Hsp60 and to p277(Val⁶-Val¹¹) in DNA-Vaccinated Mice

The process leading to the onset of diabetes in NOD mice can be arrested by administration of peptide p277, derived from the Hsp60 protein (Elias et al, 1991). Successful treatment of NOD mice with peptide p277 or its analog p277(Val⁶-Val¹¹) is associated with the induction of specific antibodies to p277, along with a decrease in the proliferation of T cells to Hsp60 and to p277 (Elias et al, 1997). The present inventors therefore assayed the splenocytes isolated from the DNA-vaccinated, or PBS-treated NOD mice to check their proliferative responses to p277(Val⁶-Val¹¹) and Hsp60. Groups of five 8-week-old female NOD mice received three weekly injections of PBS, pcDNA3 or pHsp60. Four weeks later, their spleens were removed and the T-cell proliferative responses were assayed after 72 hours of stimulation with 10 $\mu\text{g/ml}$ of human Hsp60 (Fig. 4A) or 1 $\mu\text{g/ml}$ of p277(Val⁶-Val¹¹) (Fig. 4B). The results are expressed as the stimulation index (SI) \pm SD in comparison to paired samples incubated with media alone. (a single

asterisk denotes $P < 0.01$ compared to PBS treated mice, a plus sign denotes $P < 0.05$ compared to PBS treated mice).

As shown in Figures 4A and 4B, PBS-treated NOD mice manifested spontaneous reactivities to Hsp60 (Fig. 4A) and to p277(Val⁶-Val¹¹) (Fig. 4B). In contrast, splenocytes
 5 from the mice vaccinated with pcDNA3 or pHsp60 showed diminished reactivities to p277(Val⁶-Val¹¹) ($p < 0.05$) and to Hsp60 ($p < 0.01$). However, the T cells from both the treated and the non-treated mice showed similar reactivities to Con A (not shown), thus indicating that there was no general inhibition of T cell reactivity induced by DNA vaccination. These results suggested that treatment with plasmid DNA down-regulated the
 10 spontaneous proliferative response directed to Hsp60 and p277(Val⁶-Val¹¹) characteristic of the diabetogenic process in NOD mice.

Induction of Antibodies to p277(Val⁶-Val¹¹) and to Hsp60 by DNA Vaccination

The decrease in T-cell proliferation to Hsp60 and its peptide p277 or its analog
 15 p277(Val⁶-Val¹¹) observed in NOD mice protected from diabetes by treatment with p277 or its analog is associated with the induction of antibodies directed to p277 (Elias et al, 1997). To see if the protective effect of DNA vaccination might be associated with the appearance of antibodies to Hsp60 and to p277(Val⁶-Val¹¹), the present inventors analyzed antibody responses in DNA-vaccinated animals 14 days after the last DNA injection, at the
 20 age of 14 weeks. Groups of 18 NOD mice were treated with PBS, pcDNA3, pHsp60, or CpG or GpC oligonucleotides, while one group was left untreated. Two weeks after treatment, individual sera were tested at a 1:100 dilution for the presence of specific antibodies. Fig. 5A shows serum antibodies to Hsp60 and to p277(Val⁶-Val¹¹), and Fig. 5B shows serum antibodies to GAD, insulin and GST. Data represent the mean \pm SD for each
 25 group (the asterisk denotes $P < 0.001$ compared to PBS treated mice).

Figure 5A shows that antibodies to p277(Val⁶-Val¹¹) were not detected in the sera of untreated or PBS-injected animals. The absence of antibodies to p277(Val⁶-Val¹¹) and to Hsp60 is expected in NOD mice of this age (Krause et al, 1999). Antibodies to p277(Val⁶-Val¹¹) in BALB/c mice immunized with pHsp60 were not detected, where the
 30 appearance of anti-Hsp60 antibodies was demonstrated (Figure 7 and data not shown). However, NOD mice vaccinated with pHsp60 or with pcDNA3 manifested significant

levels of antibodies to p277(Val⁶-Val¹¹) ($p < 0.001$). Thus, inhibition of diabetes in NOD mice by DNA vaccination with either pcDNA3 or pHsp60 is associated with the induction of antibodies to Hsp60 and to the peptide p277(Val⁶-Val¹¹), even though the pcDNA3 construct does not contain genetic material encoding Hsp60.

5

CpG Injection Induces Antibodies to Hsp60 and to Peptide p277(Val⁶-Val¹¹)

Bacterial DNA contains immunostimulatory sequences that are recognized by the immune system as danger signals, and trigger a series of responses in cells of both the innate and adaptive immune system (Lipford et al, 1998; Krieg et al, 19989; Krieg, 1999).

10 The pcDNA3 vector contains the immunostimulatory CpG sequence in its ampicillin resistance gene (Boccaccio et al, 1999). The present inventors tested whether a DNA oligonucleotide with two CpG sequences could induce the production of specific antibodies to Hsp60 and to p277(Val⁶-Val¹¹) that followed vaccination with pcDNA3. As a control the oligonucleotide GpC was used, in which the CpG motifs were inverted.

15 Eight-week old NOD mice were treated with the oligonucleotides CpG or GpC, and antibodies to Hsp60, p277(Val⁶-Val¹¹), GAD, insulin and GST were assayed by ELISA at the age of 14 weeks. As shown in Figure 5A, treatment with the CpG oligonucleotide induced significant levels of antibodies to Hsp60 and to p277(Val⁶-Val¹¹) ($p < 0.002$). Moreover, the titer of antibodies induced by CpG was also significant when compared to
20 the levels found in GpC treated mice ($p < 0.02$). Since the GpC oligonucleotide failed to induce specific antibodies to Hsp60 or to p277(Val⁶-Val¹¹), the induction of these specific antibodies by the pcDNA3 vector may be linked to the presence of the CpG motif. Thus, stimulation of the NOD immune system with an immunostimulatory sequence alone can trigger the production of specific autoantibodies to Hsp60 and its peptide analog
25 p277(Val⁶-Val¹¹).

It was conceivable that the appearance of antibodies to p277(Val⁶-Val¹¹) and to the Hsp60 antigen reflected a polyclonal activation of IgG-secreting clones. Therefore, the sera were assayed from the different groups of mice for antibodies to insulin, GAD and the bacterial recombinant protein GST. Figure 5B shows that the levels of antibodies to
30 insulin, GAD or GST were essentially the same among the groups. Thus, administration of the pHsp60, the pcDNA3 vector, or of the CpG oligonucleotide induced specific antibodies

to Hsp60 and to p277(Val⁶-Val¹¹). This indicates that the induction of specific antibodies to Hsp60 and to p277(Val⁶-Val¹¹) was not the result of polyclonal activation.

CpG Injection Inhibits NOD Diabetes

5 To test whether administration of the CpG oligonucleotide can, like the pcDNA3 vector, modulate the development of spontaneous diabetes in NOD mice, groups of eight-week old female NOD mice were vaccinated three times at weekly intervals, and followed their glucose levels. Figure 6 shows the cumulative incidence of diabetes. Female NOD mice were allocated to groups of 15–18 mice each, and were immunized with PBS,
10 CpG or GpC. A control group was left untreated. The CpG vaccinated group developed a significantly lower incidence of diabetes (the asterisk denotes $P < 0.015$ compared to GpC treated mice).

 It can be seen that both untreated animals and those treated with PBS developed the expected incidence of diabetes for NOD females; around 85% of them were sick by the age
15 of six months. Furthermore, the incidence of diabetes was not affected in the group of mice vaccinated with the control oligonucleotide GpC. However, the mice vaccinated with CpG showed a significant reduction in the incidence of diabetes. Only about 40% of those treated with CpG ($p < 0.015$) were diabetic at the age of six months.

 Therefore, the protective effect observed after immunization with pcDNA3 could
20 be reproduced with a DNA oligonucleotide containing CpG motifs. The mechanism involved is sequence specific, since the control oligonucleotide GpC did not have a significant effect on the incidence of the disease.

Antibody Isotypes

25 The isotype of specific serum antibodies characterizes the phenotype of the immune response to an antigen; the antibody isotype reflects the *in vivo* integration of the complex network of cytokines that regulates the immune response. Antibodies of the IgG1 and IgG2b isotypes evidence a specific Th2 response, because they are dependent on IL-4 and TGF- α , respectively (McIntyre et al, 1993; Snapper et al, 1993). In contrast, antibodies of
30 the IgG2a isotype are IFN- γ dependent, and they reveal the existence of a Th1 response (McIntyre et al, 1993; Snapper et al, 1993). Therefore, the isotypes of the antibodies to

p277(Val⁶-Val¹¹) and to Hsp60, detected in DNA-vaccinated mice 14 days after the last injection, were studied. The isotypes of serum antibodies to Hsp60 (Fig. 7A), or p277(Val⁶-Val¹¹) (Fig. 7B) from NOD (black bars, n = 18) or BALB/c (white bars, n = 5) mice treated with pcDNA3, pHsp60 or the CpG oligonucleotide were determined two weeks after the last vaccination. The isotypes of the antibodies were tested at a 1:100 dilution of individual sera. Data are shown as the mean \pm SD for each group (the asterisk denotes $P < 0.01$ compared to IgG2a levels in the same group).

Figures 7A and 7B show that the antibodies induced to Hsp60 and to p277(Val⁶-Val¹¹) were predominantly of the IgG2b isotype ($p < 0.01$ in comparison to IgG2a levels). There was also a slight increase in the levels of IgG1 antibodies to Hsp60 and p277(Val⁶-Val¹¹), but this induction was significant in comparison to the amount of the IgG2a specific antibodies only in the group treated with the CpG oligonucleotide. Furthermore, there were no differences in the isotypes of the antibodies between the pHsp60, pcDNA3 and CpG treated NOD mice. Thus, the inhibition of diabetes induced by the DNA plasmids or by the CpG oligonucleotide in both cases was accompanied by the induction of antibodies to Hsp60 and p277(Val⁶-Val¹¹) of the IgG2b isotype, characteristic of a Th2-type response.

Interestingly, there was a marked difference in the antibodies induced in the BALB/c compared to the NOD mice. The BALB/c mice made antibodies to Hsp60 when they were vaccinated with pHsp60 but not following immunization with pcDNA3 (Figure 1A). Moreover, the antibodies induced were mainly of the IgG1 subclass, and the BALB/c mice did not make antibodies to p277(Val⁶-Val¹¹). These results indicate strain-specific differences in the cytokine networks that regulate antibody secretion to the self antigen Hsp60.

Induction of IL-10 and IFN γ Secretion by the CpG Oligonucleotide

To gain some insight into the cytokine effects of CpG, the amounts of IL-10, a Th2 cytokine, and IFN γ , a Th1 cytokine, secreted by NOD spleen cells after CpG oligonucleotide stimulation *in vitro*, were assayed. Since different cytokines are secreted in different physiological amounts, included control groups of spleen cells incubated with ConA, a prototypic T-cell mitogen, were included. NOD spleen cells were incubated in

triplicates with increasing concentrations of the CpG or GpC oligonucleotides for 48 hours, and their supernatants were tested for the amounts of IFN γ , of IL-10 cytokine released. Control spleen cells were incubated with Con A, 1,25 μ g/ml, to obtain a relative response magnitude. Fig 8A shows IL-10 production, and Fig. 8B shows IFN γ production. The data are shown as the mean \pm SD of triplicates. Three independent experiments produced similar results.

As shown in Figs. 8A and 8B, the CpG oligonucleotide induced both IL-10 and IFN γ production in NOD spleen cells in a dose-dependent manner. However, when compared to the amount of cytokine released in response to Con A stimulation, the effect of CpG treatment seemed to be relatively more effective in stimulating IL-10 than in stimulating IFN γ . CpG-triggered a maximal release of IFN γ of 7 ng/ml, about one-fourth of the IFN γ released by Con A. In contrast, CpG induced the release of 1.5 ng/ml of IL-10, almost 10 times higher than the amount induced by Con A stimulation.

CpG activates spleen cells in vitro

In order to study the regulatory mechanisms involved in control of spontaneous NOD diabetes by CpG treatment, we used oligonucleotides containing one or two CpG motifs. The oligos were respectively called DP (double positive) or SP (single positive). As controls we used oligos where the CpG motifs were inverted and therefore rendered inactive. These control oligos were called DN (double negative) and SN (single negative). To check the in vitro effects of CpG motifs on spleen cells, splenocytes were prepared from normoglycemic 3-month old NOD females and incubated for 72 hrs in 96- well plates with different concentrations of control, or CpG-containing oligonucleotides. During the last 16 hrs., labelled thymidine was added to the culture medium, and at the end of the incubation period, the cells were harvested and the proliferation in response to the different stimuli was quantified. It was found that oligonucleotides containing CpG motifs (DP and SP) induce a dose-dependent proliferation. Moreover, the oligo that contains two CpG motifs (DP) induces stronger proliferations than the oligo containing a single CpG motif (SN). Control oligonucleotides where the CpG motif has been removed by inversion (DN and SN) had no significant effect. CpG induced responses are as strong as those induced with LPS.

Irradiation of the splenocytes with 3000 Rads (the standard procedure for their use as APCs in the stimulation of T-cell lines in culture) abrogated CpG-induced proliferation.

The same experiment was performed with spleens taken from NOD females at different ages. No differences were detected in the proliferative responses induced in response to CpG stimulation, either SP or DP. Furthermore, no significant differences were seen when NOD spleens were compared to C57BL/6 or BALB/c spleens taken from age and sex-matched animals. Therefore, it was confirmed that CpG induces proliferation of spleen cells, and this proliferation is inhibited by gamma irradiation.

10 **CpG upregulates Hsp60 expression**

Western blot experiments were performed to check if CpG stimulation upregulates the expression of Hsp60 on splenocytes. NOD spleen cells were isolated from normoglycemic females and stimulated in vitro for 48 hrs. with different concentrations of the DP oligo. Stimulated splenocytes were then lysed on ice for 5 minutes, and after 10 minutes of centrifugation at 14000 rpm, the supernatants (representing the cytoplasmic fraction) were analysed by Western blot using anti Hsp60 specific polyclonal antibodies. Incubation with CpG induced the expression of Hsp60 in a dose dependent manner. Therefore, the effect of CpG in inhibiting diabetes could involve the up-regulation of Hsp60 by CpG.

20

CpG induces secretion of Hsp60

The release of Hsp60 to tissue culture medium after stimulation of splenocytes by CpG was studied. NOD splenocytes were stimulated in vitro with CpG-positive (DP and SP) or control (DN and SN) oligos for 48 hrs. A capture Elisa method was used to quantify Hsp60 present in tissue culture supernatants at the end of the stimulation period. Hsp60 can, indeed, be detected in a dose-dependent manner in supernatants of splenocytes activated with CPG as presented in Figure 9). Spleen cells activated with Con A or LPS do not release Hsp60, suggesting that release of Hsp60 is a specific feature of the CpG/TLR-9 pathway, not shared with other pathways leading to T or B cell activation, even when they also signal through pattern recognition receptors (LPS/TLR-4).

30

CpG activates Hsp60-specific T-cell lines

CpG-containing oligonucleotides upregulated Hsp60 expression, and release into extracellular medium; the effect of CpG on Hsp60-specific T-cell lines in the presence of irradiated APCs was tested. NOD T-cell lines raised against two immunodominant epitopes of mammalian Hsp60, p12 and p277, and an NOD T-cell line specific to OVA as a control were used. Table 1 show that CpG-containing oligos induced T-cell proliferation. Furthermore, the number of CpG sequences present in the oligo also influenced the strength of the proliferation, since DP oligos induced stronger proliferations than did the SP oligos. No significant proliferation was observed in response to the control oligos DN and SN. The OVA-specific T-cell line did not proliferate in response to the CpG positive oligos, but all the lines proliferated in response to their appropriate antigen. LPS did not induce a significant proliferation in the presence of APCs, indicating that the T-cell line is not contaminated with non-T cells. These CpG-induced responses were inhibited by anti-MHC-class II antibodies, indicating that CpG induced proliferation involves presentation of Hsp60 epitopes in the MHC-class II molecule. Therefore, it can be concluded that CpG up-regulates Hsp60 and induces the presentation of the Hsp60 epitopes p277 and p12, that can be presented to specific T-cells and can stimulate them to proliferate.

Table 1: CpG stimulates mammalian Hsp60-specific T-cell lines.

Clones	T-cell proliferation (SI)				
	DN	DP	SN	SP	Antigen
Anti-p12	3±0.5	19± 2.6	2.5± 0.4	9.5± 1.2	41 ± 1.9
Anti- p277(Val ⁶ -Val ¹¹)	1.5±0.1	18± 1.9	1.4± 0.2	12 ± 1.5	83± 6.1
Anti-OVA	2.2±0.3	2.1±0.2	2.3± 0.5	3.1± 0.4	30 ± 3.6

NOD T cell lines specific to p277(Val⁶-Val¹¹), p12 or OVA were stimulated in vitro with CpG positive or control oligos (10 µg/ml), or with their corresponding antigens (10 µg/ml). Proliferation was measured after 72 hrs. and is expressed as stimulation index (SI).

CpG shifts the cytokines of activated T-cells to an anti-inflammatory profile

The production of cytokines in response to stimulation with CpG-containing oligonucleotides was studied. As shown in Table 2, in vitro stimulation with oligos

containing one or two CpG motifs induced the release of IL-10 and IFN γ . IL-2 or IL-4 in the supernatants of CpG-stimulated T-cell lines was not detected. When compared to the amount of cytokine released in response to peptide-specific stimulation, CpG induced secretion of higher amounts of IL-10 and lower amounts of IFN γ . The relative increase in IL-10 secretion might explain the protective effect of CpG on NOD diabetes, because IL-10 is known to have suppressor effects on the immune response (Akidis and Blaser, 2001).

Table 2: CpG-mediated T-cell activation leads to IL-10 and IFN γ secretion.

Cytokine release (pg/ml)								
	<u>Medium</u>	Con A	LPS	Antigen	DP	DN	SP	SN
IL-10	0 \pm 6	1200 \pm 45	ND	720 \pm 32	2300 \pm 134	365 \pm 27	2800 \pm 235	340 \pm 10
IFN γ	ND	70 \pm 8	11 \pm 3	114 \pm 12	43 \pm 6	19 \pm 3	37 \pm 4	21 \pm 4

P12-specific T-cells were activated in the presence of APCs for 72 hrs. with LPS (10 μ g/ml), Con A (1.25 μ g/ml), CpG positive and control oligonucleotides (10 μ g/ml) or p12 (10 μ g/ml). The supernatants were collected and secreted cytokines were measured by capture ELISA. The results are expressed as pg/ml of cytokine secreted. ND, not detected.

CpG down-regulates APC function in vivo

Experiments were performed to test whether CpG-treatment influences APC function in vivo. It was recently reported that LPS down-regulates APC function in NOD mice (Tian et al., 2001). Three-month old females were injected once with 100 μ g/mouse of an oligonucleotide containing two CpG, or a control oligonucleotide containing two inactive GpC motifs. Splenocytes were prepared from oligonucleotide- or PBS-treated animals, and then irradiated with 3000 Rads in order to use them as APCs. The APCs were coincubated with the NOD T-cell line specific for the p12 peptide of Hsp60, and then the line (in the presence of the different APCs) was stimulated either with the p12 peptide, or with the CpG or control oligonucleotides. T-cells activated in the presence of 10 μ g/ml of p12 and APCs prepared from CpG treated mice showed significantly lower SI (150 \pm 13) than those activated in the presence of APCs isolated from PBS or GpC treated mice (298 \pm 24 and 275 \pm 18, respectively). Therefore, APCs prepared from CpG-treated mice are

less efficient than those taken from GpC or PBS treated mice. There were no significance differences in the proliferative responses induced by CpG containing oligonucleotides .

In order to better understand the mechanisms underlying this apparent down-regulation of APC function, we studied the cytokines released in response to stimulation with p12 or CpG-containing oligonucleotides in the presence of the different APC preparations.

Table 3: APCs isolated from CpG-treated mice induce the release of higher levels of IL-10 and IL-5 in response to peptide stimulation.

Cytokine	Cytokine secreted (pg/ml)		
	PBS-APC + p12	GpC-APC + p12	CpG-APC + p12
IL-4	ND	18 ± 4	65 ± 13
IL-5	4300 ± 326	4253 ± 183	4156 ± 68
IL-10	ND	35 ± 5	83 ± 12
IFN γ	7225 ± 658	7465 ± 425	7736 ± 397

APCs were isolated from animals treated with oligos containing or not CpG motifs and used to stimulate a p12 specific T-cell line. After 72 hrs. of stimulation, tissue culture supernatants were collected and released cytokines were quantified using a capture Elisa.

Table 3 shows that there were no differences in the levels of IFN γ or IL-5, although there was a dose-dependent release of IL-10, a well known suppressor cytokine, and IL-4 when the p12 line was incubated with APCs taken from CpG treated mice. Therefore, CpG treatment affected APC function, leading to the generation of APCs with diminished stimulatory properties. This effect seems to be mainly mediated mainly by the secretion of IL-10, a suppressor cytokine, and also by IL-5 and IL-4.

CpG down-regulates spontaneous NOD autoimmunity

In view of the effects of CpG in vitro, experiments were designed to reveal the in vivo effects of CpG on the specific autoimmunity of NOD mice related to diabetes. An oligo containing two CpG motifs was injected once (100 μ g/mouse) to 2 month old NOD

- females. Splenocytes were prepared 1 month after treatment with the CpG or the control oligo, and the spontaneous proliferative responses to self-antigens associated with diabetes were studied (GAD, Hsp60 and insulin), and to CpG containing oligos. Table 4 shows that mice treated with the CpG-containing oligo showed decreased proliferations to Hsp60, GAD and Insulin, although no difference was seen in the proliferative response to the oligos themselves (Table 4), or to Con A, p12, p277(Val⁶-Val¹¹), p34 and p35 (data not shown). Thus, CpG treatment downregulated the spontaneous self-reactivity directed to specific diabetes-associated antigens in NOD mice.

10 **Table 4: CpG treatment downregulates NOD spontaneous self-reactivity**

In vitro stimulus	T-cell proliferation (CPM)		
	PBS	GpC	CpG
Hsp60 (25 µg/ml)	9053 ± 567	8967 ± 697	6001 ± 364
Insulin (25 µg/ml)	6397 ± 367	6354 ± 654	2860 ± 564
GAD (5 µg/ml)	25684 ± 249	23687 ± 3200	16588 ± 2799
DP (10 µg/ml)	35687 ± 4895	36479 ± 2156	34468 ± 3468
DN (10 µg/ml)	5640 ± 235	6800 ± 563	5870 ± 157
SP (10 µg/ml)	27868 ± 1254	28473 ± 2458	26498 ± 3284
SN (10 µg/ml)	10546 ± 2346	8703 ± 564	9218 ± 1166

NOD splenocytes were isolated 1 month after treatment with CpG, GpC containing oligos or PBS and their proliferative responses to self antigens and oligonucleotides were followed in vitro. The results are presented as mean cpm ± SD.

15

CpG shifts the cytokine profile of spontaneous autoimmunity

The phenotype of the immune responses to diabetes-associated self-antigens and CpG was studied. Splenocytes were isolated from oligonucleotide or PBS-treated mice, and cytokine release in response to in vitro stimulation was measured by capture-ELISA. Table 5 shows that CpG-treated mice shifted their autoimmune response towards a Th2 phenotype, with increased secretion of IL-10 and a decrease of IFN γ secreted in response to

20

restimulation with diabetes-associated antigens. A significant release of cytokines in response to incubation with the control peptide p35 was not detected. Thus, treatment with CpG shifts the spontaneous autoimmune response of NOD mice from Th1 to Th2.

5 **Table 5: CpG treatment shifts spontaneous Th1 self-reactivity to a Th2 phenotype**

	Cytokine secreted			
	IL-10 (pg/ml)		IFN γ (pg/ml)	
In vitro stimulus	CpG	GpC	CpG	GpC
Hsp60 (25 μ g/ml)	721 \pm 56	115 \pm 19	78 \pm 6	658 \pm 46
Hsp60/ p277(Val ⁶ -Val ¹¹) (25 μ g/ml)	256 \pm 35	ND	ND	1745 \pm 236
Hsp60/p12 (25 μ g/ml)	864 \pm 124	ND	ND	420 \pm 45
GAD (25 μ g/ml)	2498 \pm 364	1496 \pm 112	1678 \pm 214	3968 \pm 387
GAD/p34 (25 μ g/ml)	654 \pm 94	ND	ND	384 \pm 26
GAD/p35 (25 μ g/ml)	ND	ND	ND	ND
Insulin (25 μ g/ml)	378 \pm 36	ND	ND	1647 \pm 54

NOD splenocytes were isolated 1 month after treatment with CpG, GpC containing oligos or PBS to follow cytokine release in response to in vitro stimulation with different self-antigens. The results are presented as mean pg/ml of secreted cytokine.

10

CpG vaccination for IDDM patients

CpG vaccination for IDDM patients according to the present invention is tested in several studies. The target population for these studies is newly-diagnosed and established IDDM Patients. In these patients, CpG vaccine is expected to modulate the destructive pro-inflammatory autoimmune attack on the remaining reserve of beta-cells, allowing their survival and continued function. The maintenance of beta-cell function should result in improved metabolic control, reduced insulin requirement and reduced rate of hypoglycemic attacks. Improved metabolic control has been shown to reduce and postpone major Diabetes-related health complications during the later stage of the disease.

20

Phase I - Safety study in Established IDDM; Double-blind, Randomized, Placebo-controlled: 3 doses of CpG vaccine, 2 administrations; Dosing schedule: 0, 6 months + 7 weeks follow-up.

- 5 Phase II - Safety & Efficacy study - Established IDDM; Double-blind, Randomized, Placebo-controlled: 3 doses of CpG vaccine, 4 administrations; Dosing schedule: 0, 1, 6 & 12 months + 6 months follow-up. Patients with Basal C-peptide level equal or greater than 0.1 pmol/ml are included in this study. Tested endpoints: Stimulated C-peptide, insulin dose, HbA1C, immunological response to CpG vaccine (Th2 shift).

- 10 Phase II- Efficacy & Safety - Newly diagnosed IDDM adults; Double-blind, Randomized, Placebo-controlled: 1-3 doses of CpG vaccine, 4 administrations; Dosing schedule: 0, 1, 6 & 12 months + 6 months follow-up. Patients with basal C-peptide level equal or greater than 0.1 pmol/ml are included in this study. Tested endpoints: Stimulated C-peptide, insulin dose, HbA1C, immunological response to CpG vaccine (Th2 shift).

- 15 Phase II- Efficacy & Safety - Newly diagnosed IDDM children; Double-blind, Randomized, Placebo-controlled: 1-3 doses of CpG vaccine, 4 administrations. Dosing schedule: 0, 1, 6 & 12 months + 6 months follow-up. Patients with basal C-peptide level equal or greater than 0.1 pmol/ml are included in this study. Tested endpoints: Stimulated C-peptide, insulin dose, HbA1C, immunological response to CpG vaccine (Th2 shift).

- 20 All these clinical studies are based on the working hypothesis that CpG vaccine acts as a vaccine, requiring a limited number of administrations which were timed according to the conventional schedule for vaccines. CpG vaccine may be also administered as a therapeutic vaccine for chronic treatment and that in order to maintain the disease-specific Th1 to Th2 shift a more intensive dosing schedule is required.

- 25 The DNA vaccines for treatment of IDDM patients may further comprises DNA sequences encoding a polypeptide selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12. Additional vaccines and treatment regimens may further comprises administration of a peptide or polypeptide molecule selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12. The peptide or polypeptide molecule may be administered together with the DNA vaccine or independent or separate from the
30 DNA vaccine.

The foregoing description of the specific embodiments so fully reveals the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such

5 adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention. Thus the

10 expressions "means to..." and "means for...", or any method step language, as may be found in the specification above and/or in the claims below, followed by a functional statement, are intended to define and cover whatever structural, physical, chemical or electrical element or structure, or whatever method step, which may now or in the future exist which carries out the recited function, whether or not precisely equivalent to the embodiment or

15 embodiments disclosed in the specification above, i.e., other means or steps for carrying out the same functions can be used; and it is intended that such expressions be given their broadest interpretation.

REFERENCES:

- Ablamunits et al, "Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment", J Autoimmun 11:73 (1998)
- 5 Akdis and Blaser, "Mechanisms of interleukin-10-mediated immune suppression", Immunology 102: 131 (2001)
- Atkinson et al, "The NOD mouse model of type 1 diabetes: as good as it gets?", Nat med
10 5:601 (1999)
- Boccaccio et al, "Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis", Int Immunol 11:289 (1999)
- 15 Bockova et al, "Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies", J Autoimmun 10:323 (1997)
- Birk et al, "NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells", J Autoimmun 9:159 (1996)
- 20 Brazolot Millan et al, "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", PNAS 95:15553-15558 (1998)
- 25 Campbell et al, "Reduction in insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse", J Autoimmun 4:249 (1991)
- Carpentier et al, "Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs ", Clin Cancer Res 2000,
30 6(6):1469-73 (2000)

Cohen I., Tending Adam's Garden: Evolving the Cognitive Immune Self, Academic Press, London (2000)

5 Elias et al, "Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein", Proc Natl Acad Sci USA 88:3088 (1991)

Elias et al, "Peptide therapy for diabetes in NOD mice", Lancet 343:704 (1994)

10 Elias et al, Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277", Diabetes 44:1132 (1995)

Elias et al, "Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens", Diabetes 46:758 (1997)

15 Elias et al, "Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide", Int Immunol 11:957 (1999)

20 Gilkeson et al, "Modulation of renal disease in autoimmune NAB/NZW mice by immunization with bacterial DNA", J Exp Med 183:1389 (1996)

Hassett et al, "Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization", J Virol 74:2620 (2000)

25 Hartmann et al, "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells", PNAS 96:9305-9310 (1999)

30 King et al, "TGF-beta1 alters APC preference, polarizing islet antigen responses toward a TH2 phenotype", Immunity 8:601 (1998)

- Klinman et al, "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma", Proc Natl Acad Sci USA 93:2879 (1996)
- 5 Klinman et al, "Contribution of CpG motifs to the immunogenicity of DNA vaccines", J Immunol 158:3635 (1997)
- Krause et al, "Inhibition of diabetes in NOD mice by idiotypic induction of SLE", J Autoimmun 13:49 (1999)
- 10 Krieg et al, "The role of CpG dinucleotides in DNA vaccines", Trends Microbiol 6:23 (1998)
- Krieg et al, "CpG DNA: a novel immunomodulator [letter]", Trends Microbiol 7:64
15 (1999)
- Lipford et al, "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", European Journal of Immunology 27:(9)2340-2344 (1997)
- 20 Lipford et al, "Bacterial DNA as immune cell activator", Trends Microbiol 6:496 (1998)
- McIntyre et al, "Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells", J Exp Med
25 177:1031 (1993)
- Nicoletti et al, "Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats", Diabetes 47:32 (1998)

- Raz et al (1996), "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization", PNAS 93:5141-5145.
- 5 Rothe et al, "IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulinitis", J Immunol 163:1230 (1999)
- 10 Serreze et al, "Immunostimulation circumvents diabetes in NOD/Lt mice", J Autoimmun 2:759 (1989)
- Sobel et al, "Low dose poly I:C prevents diabetes in the diabetes prone BB rat", J Autoimmun 11:343
- 15 Snapper et al, "Towards a comprehensive view of immunoglobulin class switching", Immunol Today 14:15 (1993)
- Stevenson et al, "DNA vaccination against multiple myeloma", Semin Hematol 36:38 (1999)
- 20 Tascon et al, "Vaccination against tuberculosis by DNA injection", Nat Med 2:888 (1996)
- Tian et al. "Lipopolysaccharide-activated b cells down-regulate th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice" J. Immunology 167:1081 (2001)
- 25 Tisch et al, "Insulin-dependent mellitus", Cell 85:291 (1996)
- 30 Waisman et al, "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity", Nat Med 2:899 (1996)

Weiner et al, "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", PNAS 94:10833-10837 (1997)

- 5 Wolff et al, "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle", Hum Mol Genet 1:363 (1992)

10 Wooldridge et al, "Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma", Blood, 89:2994-2998 (1997)

Yang et al, "Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process", J Exp Med 180:995 (1994)

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treatment of an ongoing autoimmune disease, comprising vaccinating a
5 patient having an autoimmune disease with an effective amount of a DNA vaccine
comprising a DNA molecule with a sequence comprising a CpG motif.
2. The method in accordance with claim 1, wherein said autoimmune disease is
insulin-dependent diabetes mellitus.
3. The method in accordance with claim 1, wherein said DNA molecule has a sequence
10 comprising the dinucleotide CG flanked at the 5' side by two purines and at the 3' side
by two pyrimidines.
4. The method in accordance with claim 3, wherein said sequence comprises AACGTT.
5. The method in accordance with claim 2, wherein said DNA vaccine further comprises
DNA sequences encoding a peptide or a polypeptide selected from the group consisting
15 of Hsp60, p277, p277(Val⁶-Val¹¹) and p12.
6. The method in accordance with claim 2, further comprising the step of administering a
peptide or a polypeptide molecule selected from the group consisting of Hsp60, p277,
p277(Val⁶-Val¹¹) and p12.
7. The method of claim 6 wherein the peptide or polypeptide is co-administered with the
20 DNA vaccine.
8. The method of claim 6 wherein the a peptide or polypeptide is administered separately
from the DNA vaccine.
9. A method for prevention of an autoimmune disease, comprising vaccinating an
individual in need of such prevention with an effective amount of a DNA vaccine
25 comprising a DNA molecule with a sequence comprising a CpG motif.

10. The method in accordance with claim 9, wherein said autoimmune disease is insulin-dependent diabetes mellitus.
11. The method in accordance with claim 9, wherein said DNA vaccine has a sequence comprising the dinucleotide CG flanked at the 5' side by two purines and at the 3' side by two pyrimidines.
12. The method in accordance with claim 11, wherein said sequence comprises AACGTT.
13. The method in accordance with claim 9, wherein said DNA vaccine further comprises DNA sequences encoding a peptide or a polypeptide selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12.
14. The method in accordance with claim 9, further comprising the step of administering a peptide or a polypeptide molecule selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12.
15. The method of claim 14 wherein the peptide or polypeptide is co-administered with the DNA vaccine.
16. The method of claim 14 wherein the peptide or polypeptide is administered separately from the DNA vaccine.
17. Use of a DNA molecule comprising a CpG motif for the preparation of a vaccine for treatment or prevention of an ongoing autoimmune disease.
18. Use in accordance to claim 17, wherein said autoimmune disease is insulin-dependent diabetes mellitus.
19. Use in accordance to claim 17, wherein said DNA molecule has a sequence comprising the dinucleotide CG flanked at the 5' side by two purines and at the 3' side by two pyrimidines.
20. Use in accordance to claim 19, wherein said sequence comprises AACGTT.

21. Use in accordance with claim 17, wherein said DNA vaccine further comprises DNA sequences encoding a peptide or a polypeptide selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12.
22. Use in accordance with claim 17, wherein said vaccine further comprises a peptide or a polypeptide molecule selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12.
23. A DNA vaccine comprising DNA sequences encoding a peptide or polypeptide antigen associated with IDDM.
24. The DNA vaccine according to claim 24, wherein said CpG motif further comprises DNA sequences encoding a peptide or a polypeptide selected from the group consisting of Hsp60, p277, p277(Val⁶-Val¹¹) and p12.
25. The DNA vaccine according to claim 23 further comprises a CpG motif.
26. The DNA vaccine according to claim 24, wherein said CpG motif has a sequence comprising the dinucleotide CG flanked at the 5' side by two purines and at the 3' side by two pyrimidines.
27. The DNA vaccine according to claim 24, wherein said CpG motif comprises AACGTT.

1/9

FIGURE 1A






FIGURE 1B




2/9

FIGURE 2



3/9

FIGURE 3



4/9

FIGURE 4A





FIGURE 4B



5/9

FIGURE 5A






FIGURE 5B



6/9

FIGURE 6



7/9

FIGURE 7A





FIGURE 7B



8/9

FIGURE 8A






FIGURE 8B



9/9



SEQUENCE LISTING

<110> YEDA RESEARCH AND DEVELOPMENT CO. LTD.

<120> METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE

<130> IC/018/PCT

<150> US 60/227853

<151> 2000-08-25

<160> 5

<170> PatentIn version 3.0

<210> 1

<211> 5446

<212> DNA

<213> unknown

<220>

<223> artificial sequence

<400> 1

gacggatcgg gagatctccc gatcccctat ggctgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg ctgtgtgtgt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggtag gcgtttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacgggggc attagttcat agcccatata 300
tggagtccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgcca cttggcagta catcaagtg 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600
tcgctattac catggtgatg cggtttggc agtacatcaa tgggcgtgga tagcggttg 660
actcacgggg atttcaagt ctccaccca ttgacgtcaa tgggagttg tttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
 gtaggcgtgt acgggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
 ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gcttggtagc 900
 gagctcggat ccactagtaa cggccgccag tgtgctggaa ttctgcagat atccatcaca 960
 ctggcgggcg ctgagcatg catctagagg gccctattct atagtgtcac ctaaagtcta 1020
 gagctcgtg atcagcctcg actgtgcctt ctagtgtcca gccatctgtt gtttggccct 1080
 cccccgtgcc ttccitgacc ctggaagggtg ccactccac tgtcctttcc taataaaatg 1140
 aggaaattgc atgcattgt ctgagtaggt gtcattctat tctgggggggt ggggtggggc 1200
 aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat gcggtgggct 1260
 ctatggcttc tgaggcggaa agaaccagct ggggctctag ggggtatccc cagcgccct 1320
 gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc gctacacttg 1380
 ccagcgccct agcgcccgct ctttcgctt tcttcccttc ctttctgcc acgttcgccg 1440
 gcttccccg tcaagctcta aatcggggca tcccttagg gticcgtatt agtgctttac 1500
 ggcacctga ccccaaaaaa ctgattagg gtgatggctc acgtagtggg ccatcgccct 1560
 gatagacggg ttttcgccct ttgacgttg agtccacgtt cttaatatg ggactctgt 1620
 tccaaactgg aacaacactc aacctatct cggctctatt tttgattta taagggtatt 1680
 tggggatttc ggcctattgg ttaaaaaatg agctgattta acaaaaattt aacgcgaatt 1740
 aattctgtgg aatgtgtgtc agttaggggtg tggaaagtcc ccaggctccc caggcaggca 1800
 gaagtatgca aagcatgcat ctcaattagt cagcaaccag gtgtggaaag tcccaggct 1860
 cccagcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc atagtcccgc 1920
 ccctaactcc gcccatcccg ccctaactc cgccagttc cgccattct ccgccccatg 1980
 gctgactaat ttttttatt tatgcagagg ccgaggccgc ctctgcctct gagctattcc 2040
 agaagtagtg aggaggcttt ttggaggcc taggcttttg caaaaagctc ccgggagctt 2100
 gtatatccat ttccgatct gatcaagaga caggatgagg atcgtttcgc atgattgaac 2160
 aagatggatt gcacgcaggt tctccggccg ctgggtgga gaggctattc ggctatgact 2220

gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca ggcgaggggc 2280
gcccggttct tttgtcaag accgacctgt ccggtgccct gaatgaactg caggacgagg 2340
cagcgcggt atcgtggctg gccacgacgg gcgttccttg cgcagctgtg ctgacgttg 2400
tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag gatctcctgt 2460
catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg cggcgggtgc 2520
atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcg atcgagcgag 2580
cacgtactcg gatggaagcc ggtctgtcg atcaggatga tctggacgaa gagcatcagg 2640
ggctcgcgcc agccgaactg ttgccaggc tcaaggcgcg catgcccgcac ggcgaggatc 2700
tcgtcgtgac ccatggcgat gcctgctgc cgaatatcat ggtggaaaat ggccgctttt 2760
ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac atagcgttgg 2820
ctacccgtga tattgtgaa gagcttggcg gcgaatgggc tgaccgcttc ctctgtcttt 2880
acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt gacgagtct 2940
tctgagcggg actctgggtt tcgaaatgac cgaccaagcg acgccaacc tgccatcacg 3000
agatttcgat tccaccgccc ccttctatga aaggttgggc ttgggaatcg tttccggga 3060
cgccggctgg atgatctcc agcgcgggga tctcatgctg gagttcttcg cccaccccaa 3120
ctgtttatt gcagcttata atggttaca ataaagcaat agcatcaca atttcacaaa 3180
taaagcattt tttcactgc attctagtgt tggttgtcc aaactcatca atgtatctta 3240
tcatgtctgt ataccgtga cctctagcta gagcttggcg taatcatggt catagctgtt 3300
tcctgtgtga aattgttatc cgctcacaat tccacacaac atacgagccg gaagcataaa 3360
gtgtaaagcc tggggtgcct aatgagttag ctaactcaca ttaattgcgt tgcgtcact 3420
gcccgtttc cagtcgggaa acctgtctg ccagctgcat taatgaatcg gccaacgcgc 3480
ggggagaggc ggtttgcgta ttgggcgctc ttccgcttcc tcgctcactg actcgtgcg 3540
ctcggctgtt cggctgcggc gagcggatc agtcactca aaggcggtaa tacggttatc 3600
cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc aaaaggccag 3660

gaaccgtaaa aaggccgcgt tgctggcggt ttccatagg ctccgcccc ctgacgagca 3720
tcacaaaaat cgacgctcaa gtcagagggt gcgaaacccg acaggactat aaagatacca 3780
ggcgtttccc cctggaagct cctcgtgcg ctctcgtgt ccgaccctgc cgcttaccgg 3840
atacctgtcc gcctttctcc ctccgggaag cgtggcgctt tctcaatgt cacgctgtag 3900
gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg aacccccgt 3960
tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gattccaacc cggttaagaca 4020
cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga ggtatgtagg 4080
cgggtctaca gatttctga agtggggcc taactacggc tacactagaa ggacagtatt 4140
tggtatctgc gctctctga agccagttac ctccgaaaa agagttgga gctcttgatc 4200
cggcaaacaa accaccgctg gtagcgggtg ttttttgtt tgcaagcagc agattacgcg 4260
cagaaaaaaaa ggtatcaag aagatcctt gatctttct acggggtctg acgctcagt 4320
gaacgaaaac tcacgttaag ggatttgggt catgagatta taaaaagga tctcaccta 4380
gatccttta aattaaaaat gaagtttaa atcaatctaa agtatatatg agtaaactg 4440
gtctgacagt taccaatgt taatcagtga ggcacctatc tcagcgatct gtctatttcg 4500
ttcatccata gttgcctgac tcccgcgtg gtagataact acgatacggg agggcttacc 4560
atctggcccc agtctgcaa tgataccgcg agaccacgc tcaccggctc cagatttatc 4620
agcaataaac cagccagccg gaagggccga gcgcagaagt ggtctgcaa cttatccgc 4680
ctccatccag tctattaatt gttgccgga agctagagta agtagttgc cagttaatag 4740
tttgcgcaac gttgttgcca ttgtacagg catcgtggtg tcacgctcgt cgttggtat 4800
ggcttcattc agtccggtt cccaacgatc aaggcgagtt acatgatccc ccatgtgtg 4860
caaaaaagcg gttagctct tcggtcctcc gatcgtgtc agaagtaagt tggccgcagt 4920
gttatcactc atggttatgg cagcactgca taattctct actgtcatgc catccgtaag 4980
atgccttct gtgactgggt agtactcaac caagtcattc tgagaatagt gtatgcggcg 5040
accgagttgc tctgccccg cgtcaatacg ggataatacc gcgccacata gcagaactt 5100
aaaagtgtc atcattggaa aacgttctc ggggcgaaaa ctctcaagga tcttaccgt 5160

gttgagatcc agtfcgatgt aaccactcg tgcacccaac tgatcttcag catcttttac 5220
 tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa aaaagggaat 5280
 aagggcgaca cggaaatgtt gaatactcat actcttcctt ttcaatatt attgaagcat 5340
 ttatcagggt tattgtctca tgagcggata catatttgaa tgtatttaga aaaataaaca 5400
 aatagggggt ccgcgcacat tccccgaaa agtgccacct gacgtc 5446

<210> 2
 <211> 23
 <212> DNA
 <213> unknown

<220>
 <223> artificial sequence

<400> 2
 tccataacgt tgcaaacgtt ctg 23

<210> 3
 <211> 23
 <212> DNA
 <213> unknown

<220>
 <223> Artificial sequence

<400> 3
 tccataagct tgcaaagctt ctg 23

<210> 4
 <211> 24
 <212> PRT
 <213> unknown

<220>
 <223> Artificial sequence

<400> 4

Val Leu Gly Gly Gly Val Ala Leu Leu Arg Val Ile Pro Ala Leu Asp
 1 5 10 15

Ser Leu Thr Pro Ala Asn Glu Asp
20

<210> 5

<211> 20

<212> PRT

<213> unknown

<220>

<223> Artificial sequence

<400> 5

Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala Asn Gly Asp Lys Asp
1 5 10 15

Ile Gly Asn Ile
20

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/016549 A3

(51) International Patent Classification⁷: **A61K 38/00**,
48/00

(21) International Application Number: PCT/IL01/00790

(22) International Filing Date: 23 August 2001 (23.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/227,853 25 August 2000 (25.08.2000) US

(71) Applicant (for all designated States except US): YEDA
RESEARCH AND DEVELOPMENT CO. LTD.
[IL/IL]; P.O. Box 95, Rehovot 76100 (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COHEN, Irun, R.
[US/IL]; 11 Hankin Street, Rehovot 76354 (IL). QUIN-
TANA, Francisco, J. [AR/AR]; Teniente B Matienzo,
1831 1H Capital Federal, 1426 (AR).

(74) Agent: WEBB, Cynthia; Webb, Ben-Ami & Associates,
P.O. Box 2189, Rehovot 76121 (IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
18 July 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING
POLYNUCLEOTIDE

(57) Abstract: The present invention relates to DNA vaccines useful for the prevention and treatment of ongoing autoimmune dis-
eases. The compositions and methods of the invention feature the CpG oligonucleotide, preferably in a motif flanked by two 5'
purines and two 3' pyrimidines. The vaccine may further comprise DNA encoding a specific antigen, or the peptide antigen itself.
The invention is exemplified for IDDM.

WO 02/016549 A3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL01/00790

A. CLASSIFICATION OF SUBJECT MATTER												
IPC(7) : A61K 38/00, 48/00 US CL : 514/2, 44												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/2, 44												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online, Medline												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	LOBELL et al. Presence of CpG DNA and the Local Cytokine Milieu Determine the Efficacy of Suppressive DNA Vaccination in Experimental Autoimmune Encephalomyelitis. J. Immunology. 01 November 1999, Vol. 163, No. 9, pages 4754-4762, see entire document.	1, 3, 4, 11, 17, 19, 20										
—												
Y		13, 14, 21, 22										
X	COON et al. DNA Immunization to Prevent Autoimmune Diabetes. J. Clin. Invest. July 1999, Vol. 104, No. 2, pages 189-194, see entire document.	23										
—												
Y		1-22, 25										
Y	BOCKOVA et al. Treatment of NOD Diabetes with a Novel Peptide of the hsp60 Molecule Induces Th2-type Antibodies. J. Autoimmunity. August 1997, Vol. 10, No. 4, pages 323-329, see entire document.	1-23, 25										
Y	LIPFORD et al. Bacterial DNA as Immune Cell Activator. Trends in Microbiology. December 1998, Vol. 6, No. 12, pages 496-500, see entire document.	1-3, 9-11, 17-19										
Y	SHEHADEH et al. Effect of Adjuvant Therapy on the Development of Diabetes in Mouse and Man. The Lancet. 19 March 1994, Vol. 343, pages 706-707, see entire document.	1-3, 9-11, 17-19										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 02 May 2002 (02.05.2002)		Date of mailing of the international search report 24 MAY 2002										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer John L. LeGuyader Telephone No. (703) 308-0196										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL01/00790

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	QUITANA et al. Vaccination with Empty Plasmid DNA or CpG Oligonucleotide Inhibits Diabetes in Nonobese Diabetic Mice: Modulation of Spontaneous 60-kDa Heat Shock Protein Autoimmunity. J. Immunology. 01 December 2000, Vol. 165, No. 11, pages 6148-6155, see entire document.	1-23, 25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL01/00790

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 24, 26, 27
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.